Page 210 - Read Online

Trends in gender by years and histology, we found more early stage patients with
NSCLC (P = 0.015). SCLC was related to the advanced
Only 59 (8.4%) patients were women [Figure 1]. stage. Genetic testing for EGFR and other NSCLC-driving
This low incidence was maintained across the years. mutations was performed only for Stage IV patients, with
We found a slight increase in women patients from only EGFR and ALK being analyzed. Only ADC had
2010 to 2014 (P = 0.045). A ratio of almost 9:1 was EGFR-activating mutations (4% of all ADC, 3.2% all
maintained across the years. Female was related to NSCLC, Stage IV). Female ADC was related to EGFR
younger age (P = 0.001), histology (ADC and small cell: mutation (11 patients, 36% of women). Only 1.7% of
P = 0.001), Stage IV (P = 0.02) [Table 2].
ADC in men had EGFR mutations. No patients in our
Distribution by histological type series had ALK rearrangement.
Histology related to smoking habit (SCLC and Overall survival
squamous cell lung cancer [SQCLC]) was predominated Survival time was ascertained for all patients. Median
(121, 17.2% SCLC and 291, 41.5% SQCLC) [Table 1].
overall survival (OS) for the entire series was
Histologic trends by years

Trends through years showed a decline in SQCLC.
Although it was the main histology (incidence 37-45%),
in later years, we found a signifi cant increase in
ADC (32-40%) and a signifi cant and relevant increase in
SCLC (last date near 20-25%) (P = 0.0001) [Figure 2].
Stage trends by years
A tendency of an increase of earlier stages in the last years
is shown in Figure 3 (P = 0.063). There was also a decrease
in Stage IV and an increase of Stage III patients. Stage was
related to gender (female and Stage IV, P = 0.024). For Figure 1: Trends in gender by year
histology and stage, we found a relationship (P = 0.03)
between squamous cell and Stage III and between ADC
and Stage IV. When we studied correlations between stages

Table 2: Comparison between men and women
Male n (%): Female: n (%): Chi-square
633 (90.3%) 68 (9.7%) Pearson
Age, years
Mean (range) 68 (34-94) 63.3 (34-88) P = 0.000
Median 70 61
Mode 70 48
Histology, n (%)
Unconfi rmed 23 (3.6) 1 (1.5) P = 0.000
Small cell 109 (17.2) 10 (14.7)
Non-small cell
Squamous 288 (45.5) 4 (5.9)
Adenocarcinoma 146 (23.1) 41 (60.3) Figure 2: Trends in histology by year
Bronchoalveolar 0 1 (1.5)
Large cell carcinoma 39 (6.2) 4 (5.9)
Carcinoma not typed 9 (1.4) 6 (8.8)
Sarcoma-squamous 3 (0.5) 0
(carcinosarcoma)
Neuroendocrine 10 (1.6) 1 (1.5)
tumors
Mesothelioma 6 (0.9) 0
Stage at diagnosis
0 0 1 (0.6) P = 0.02
I 66 (10.4) 7 (10.3)
II 48 (7.6) 4 (5.9)
III 162 (25.6) 8 (11.8)
IV 357 (56.4) 49 (71.4)
Figure 3: Stage trends by years
Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦ 203